Clinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study

Our plain-English summary of Clinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study, by A. Avilés-Salas, D.D. Dupont, A. Aranda-Gutierrez, et al (BMC Cancer, 2026).

The study

• Authors: A. Avilés-Salas, D.D. Dupont, A. Aranda-Gutierrez, A.N. Heredia-Jara, E. Caballé-Perez, L. Cabrera-Miranda, A.F. Cardona, J. Lucio-Lozada, C. Castillo-Ruiz, N. Hernandez-Pedro, L. Corrales, C. Martin, O. Arrieta
• Journal: BMC Cancer
• Published: 2026;26(1)
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited treatment options. Recently, GATA3 has emerged as a useful adjunct immunohistochemical marker, especially for non-epithelioid subtypes. Although the diagnostic and prognostic roles of GATA3 have been described in other malignancies, its frequency and clinical relevance in MPM remains unclear. METHODS: We conducted a retrospective, single-center cohort study of 91 patients with histologically confirmed MPM and suitable tumor tissue for GATA3 immunohistochemistry. Staining intensity was scored semi-quantitatively (mild, moderate, or strong). Clinical, pathological, and treatment data were collected. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier methods and Cox regression models. RESULTS: GATA3 expression was observed in 64 of 91 cases (70.3%). No differences in PFS or OS were observed according to GATA3 positivity. GATA3 positivity demonstrated the ability to discrimine MPM and LUAD, with area under the curve (AUC) values of 0.83 for overall MPM, 0.81 for epithelioid MPM, and 0.93 for non-epithelioid MPM. The diagnostic performance was further improved by Combining GATA3 with WT1, yielding AUC values of 0.94 for MPM, 0.93 for epithelioid MPM, and 1.00 for non-epithelioid MPM. High GATA3 staining intensity was associated with shorter median PFS (6.14 vs. 10.94 months; p = 0.023) and OS (7.89 vs. 33.35 months; p = 0.004) compared with cases showing low or moderate intensity. High GATA3 staining intensity remained an independent adverse prognostic factor for OS (HR 6.59; 95% CI 1.55–28.05; p = 0.011) in a multivariate analysis adjusted for asbestos exposure, ECOG PS, clinical stage, PD-L1 positivity, and histological type. CONCLUSION: GATA3 is frequently expressed in MPM and demonstrates good diagnostic performance differentiating MPM from LUAD. Furthermore, high GATA3 staining intensity was independently associated with a poorer prognosis. These findings support GATA3 diagnostic utility and suggest a potential prognostic role in MPM that warrants validation in larger, prospective cohorts.

In plain English

This retrospective study from one Mexico City cancer center tested tumor tissue from 91 patients with malignant pleural mesothelioma, diagnosed 2010–2022, for a protein called GATA3. About half (50.5%) had recorded asbestos exposure. GATA3 was found in 64 of 91 tumors (70.3%). The researchers compared them with 40 lung adenocarcinomas that had spread to the pleura, 36 of which had a GATA3 result. GATA3 told the two cancers apart with an area under the curve of 0.83 (1.00 would be perfect). Combining GATA3 with a second marker, WT1, gave 0.94, but only 35 mesothelioma and 19 lung adenocarcinoma cases had both results. Survival did not differ between GATA3-positive and GATA3-negative tumors, and asbestos exposure was not associated with survival. Among GATA3-positive tumors, strong staining was associated with shorter median overall survival than low or moderate staining (7.89 vs. 33.35 months). After adjustment for asbestos exposure, performance status, stage, PD-L1 and tumor type, the hazard ratio was 5.46 (95% CI 1.11–26.9). The authors noted the retrospective design and small subgroups, and concluded that the survival link needs confirmation in larger, prospective studies.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Retrospective, single-center observational cohort study using a historical database, with a lung adenocarcinoma comparator group for the diagnostic analysis
• Who was studied: 91 of 134 malignant pleural mesothelioma (MPM) cases identified at the Thoracic Oncology Unit of the Instituto Nacional de Cancerología, Mexico City, 2010–2022, with tumor tissue available. 69.2% were male and 80.2% had epithelioid histology. The comparator group was 40 patients with lung adenocarcinoma metastatic to the pleura from the same unit and period.
• Exposure: The main factor studied was GATA3 staining of tumor tissue (positive or negative, and staining intensity). Asbestos exposure (fiber type not stated) was recorded as a clinical characteristic: present in 46 of 91 patients (50.5%). Tobacco smoke exposure was recorded in 52.7%.
• Main results:
  • GATA3 was positive in 64 of 91 MPM cases (70.3%). Staining was mild in 18 (19.7%), moderate in 26 (28.5%) and strong in 20 (21.9%).
  • In distinguishing MPM from lung adenocarcinoma, GATA3 positivity had AUC values of 0.83 for all MPM, 0.81 for epithelioid MPM and 0.92 for non-epithelioid MPM. For GATA3, all 91 MPM cases were evaluated, but only 36 of the 40 lung adenocarcinoma cases (4 missing).
  • Combined positivity for GATA3 and WT1 gave AUC values of 0.94 for MPM, 0.93 for epithelioid MPM and 1.00 for non-epithelioid MPM. For the overall MPM comparison, only 35 MPM cases (56 missing) and 19 lung adenocarcinoma cases (21 missing) had both markers evaluated.
  • For the whole cohort, median progression-free survival was 9.8 months (95% CI 6.4–11.9) and median overall survival was 21.5 months (95% CI 15.2–41.6).
  • Asbestos exposure, sex, age, smoking, wood smoke exposure, histology and disease stage were not associated with progression-free or overall survival.
  • Progression-free and overall survival did not differ between GATA3-positive and GATA3-negative MPM.
  • Among GATA3-positive tumors, high staining intensity (20 patients) was associated with shorter median survival than low or moderate intensity (44 patients). Median PFS was 6.14 vs. 10.94 months (p = 0.023), and median OS was 7.89 vs. 33.35 months (p = 0.004).
  • In multivariable analysis for overall survival, high GATA3 intensity had a hazard ratio of 5.46 (95% CI 1.11–26.9; p = 0.037). The model was adjusted for asbestos exposure, ECOG performance status, clinical stage, PD-L1 positivity and histological type.
  • In the multivariable model for progression-free survival, high versus low or moderate GATA3 intensity was not statistically significant (HR 2.06; 95% CI 0.58–7.29; p = 0.261).
• The authors' conclusion: The authors concluded that GATA3 could serve as both a diagnostic and a prognostic biomarker in mesothelioma, but that its association with survival requires validation in larger, prospective studies.
• Limitations the authors state:
  • Retrospective design, and possible residual confounding from unmeasured variables
  • Small sample size in certain histologic subgroups
  • GATA3 cannot reliably tell the MPM histologic subtypes apart, which limits it as a standalone biomarker
  • Recorded asbestos exposure was lower than the historically reported rate of about 80%. The authors attributed this to self-reported exposure in clinical records, which can lead to underestimation.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: GATA3, Pleural Mesothelioma, Cohort Study, Prognosis, Non-epithelioid, Immunohistochemistry, Progression-Free Survival, Overall Survival.

Related studies

• The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas — S. Prabhakaran, A. Hocking, et al. (2020)
• GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors — M. Miettinen, P.A. McCue, et al. (2014)
• GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas — D.G. Davis, M.T. Siddiqui, et al. (2016)
• GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung — K.B. Berg, A. Churg (2017)
• Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung — Y. Hattori, A. Yoshida, et al. (2015)
• GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis — Z.H. Piao, X.C. Zhou, et al. (2021)

Browse more research in BMC Cancer, or return to medical research.